Helping Patients Afford SYLVANT®

Support for Patients Using Commercial or Private Insurance

Janssen CarePath Savings Program for SYLVANT®

Janssen CarePath Savings Program can help eligible patients save on their out-of-pocket medication costs for SYLVANT®. Depending on their health insurance plan, savings may apply toward co-pay, co-insurance, or deductible. For SYLVANT®, your eligible patients will pay $5 per infusion with a $20,000 maximum program benefit per calendar year. The program does not cover the cost to give patients their infusion. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. See full eligibility requirements.

Get your eligible patients started today. Visit the Janssen CarePath Provider Portal to create an account and you can:

  • Enroll your eligible, commercially insured patients in the Janssen CarePath Savings Program
  • At your patient's request, upload EOB from the insurance provider to request a Savings Program rebate on behalf of the patient
  • Review your patients' available benefits
  • View patient transaction history and claims status
  • Receive timely alerts and program updates

By using the Janssen CarePath Provider Portal, you agree that you are receiving access to information about your patient's Savings Program account to assist in program administration as requested by the patient. You further agree that access to this information will not influence your clinical decisions.

Patients can also create their own Janssen CarePath Account where they can enroll in the Janssen CarePath Savings Program, learn about their insurance coverage for SYLVANT®, and sign up for personalized treatment reminders. Encourage your patient to sign up today at MyJanssenCarePath.com.

Support for Patients using Government-funded Healthcare Programs or Patients without Health Coverage

Janssen CarePath can provide information about other resources that may be able to help your patients with their out-of-pocket medication costs, including State-Sponsored Programs, Medicare Savings Program, Medicare Part D Extra Help — Low-Income Subsidy, and independent foundations.* Call Janssen CarePath at 877-CarePath (877-227-3728) to speak with a Care Coordinator about affordability programs that may be available.

Janssen Prescription Assistance for SYLVANT®

JanssenPrescriptionAssistance.com provides information on affordability programs and up-to-date information about independent foundations* that may have funding available to help your patients with medication costs for SYLVANT®.

*Independent co-pay assistance foundations have their own rules for eligibility. We have no control over these independent foundations and can only refer your patients to a foundation that supports their disease state. We do not endorse any particular foundation.

Other Resources

The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, non-profit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. To see if they might qualify for assistance, please have your patient contact a JJPAF program specialist at 1-800-652-6227 (Monday-Friday, 9 AM to 6 PM ET) or visit the foundation website at www.JJPAF.org.

Indication

SYLVANT® (siltuximab) is indicated for the treatment of patients with Multicentric Castleman's Disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

Limitation of Use. SYLVANT® was not studied in patients with MCD who are HIV-positive or HHV-8 positive because SYLVANT® did not bind to virally produced IL-6 in a nonclinical study.

Important Safety Information For SYLVANT®

CONTRAINDICATIONS – Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT®. Hypersensitivity reactions, including anaphylactic reaction, hypersensitivity, and drug hypersensitivity have been reported in patients treated with siltuximab.

Concurrent Active Severe Infections – Do not administer to patients with severe infections until the infection resolves. SYLVANT® may mask signs and symptoms of acute inflammation including suppression of fever and of acute phase reactants such as C-reactive protein (CRP). Monitor patients closely for infections. Institute prompt anti-infective therapy and do not administer further SYLVANT® until the infection resolves.

Vaccinations – Do not administer live vaccines to patients receiving SYLVANT® because interleukin-6 (IL-6) inhibition may interfere with the normal immune response to new antigens.

Infusion Related Reactions and Hypersensitivity – SYLVANT® may cause infusion related reactions and anaphylaxis. In clinical trials, one out of approximately 945 patients experienced an anaphylactic reaction. Infusion related reactions were reported in 5.1% of 254 patients. Two (0.8%) were Grade 3 or higher, and 1 (0.4%) was serious; none were fatal. Symptoms of infusion reactions consisted of back pain, chest pain or discomfort, nausea and vomiting, flushing, erythema, and palpitations.

In long-term treatment of MCD patients with siltuximab at the recommended dosage of 11 mg/kg every 3 weeks, infusion related reactions or hypersensitivity reactions occurred at a frequency of 6.3% (1.3% for severe reactions).

Stop the infusion if the patient develops signs of anaphylaxis. Discontinue further therapy with SYLVANT®.

Stop the infusion if the patient develops a mild to moderate infusion reaction. If the reaction resolves, the infusion may be restarted at a lower infusion rate. Consider medication with antihistamines, acetaminophen, and corticosteroids. Discontinue SYLVANT® if the patient does not tolerate the infusion following these interventions.

Administer SYLVANT® in a setting that provides resuscitation equipment, medication, and personnel trained to provide resuscitation.

Gastrointestinal (GI) Perforation – Use with caution in patients who may be at increased risk for GI perforation. Promptly evaluate patients presenting with symptoms that may be associated with or suggestive of GI perforation.

Adverse Reactions – The most common adverse reactions (>10% compared to placebo) in the MCD clinical trial were rash (28%), pruritus (28%), upper respiratory tract infection (26%), increased weight (19%), and hyperuricemia (11%).

Drug Interactions Cytochrome P450 (CYP450) Substrates – Upon initiation or discontinuation of SYLVANT®, in patients being treated with CYP450 substrates with narrow therapeutic index, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) as needed and adjust dose. Exercise caution when SYLVANT® is co-administered with CYP3A4 substrate drugs where a decrease in effectiveness would be undesirable (e.g., oral contraceptives, lovastatin, atorvastatin).

Please click here to read full Prescribing Information for SYLVANT®.

cp-61150v1